By Daniella Parra Sparrow Pharmaceuticals said it initiated a Phase 2 ACSpire study for SPI-62, a potent HSD-1 inhibitor, targeting autonomous cortisol secretion (ACS). ACS results from excessive cortisol production due to benign adrenal tumors and can lead to severe health issues. The company said that the study assesses SPI-62’s impact on ACS-related conditions, enrolling […]
Read full NASCAR article on Yahoo Sports
Read all NASCAR articles